Hepatic steatosis in HIV/HCV co-infected patients: Correlates, efficacy and outcomes of anti-HCV therapy: A paired liver biopsy study

Journal of Hepatology

Volumn 48, Issue 5, 2008, Pages 756-764

  Rodríguez Torres, Maribel ^a   Govindarajan, Sugantha ^b   Solá, Ricard ^c   Clumeck, Nathan ^d   Lissen, Eduardo ^e   Pessôa, Mário ^f   Buggisch, Peter ^g   Main, Janice ^h   DePamphilis, Jean ⁱ   Dieterich, Douglas T ^j  

^a Fundacion de Investigacion de Diego   (United States)

^b RANCHO LOS AMIGOS NATIONAL REHABILITATION CENTER   (United States)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS   (Brazil)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h ST MARY S HOSPITAL   (United Kingdom)

ⁱ HOFFMANN LA ROCHE INC   (United States)

^j MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Efficacy of therapy; HCV HIV; Steatosis

Indexed keywords

ALPHA2A INTERFERON; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; PEGINTERFERON ALPHA2A; RIBAVIRIN; TRIACYLGLYCEROL; VIRUS RNA;

ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NECK; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BIOPSY; BODY COMPOSITION; FATTY LIVER; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 41249092708     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.01.015     Document Type: Article

References (42)

1. Adinolfi L., Gambardella M., Andreana A., Tripodi M.F., Utili R., and Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33 (2001) 1358-1364
2. Weinman S.A., and Belalcazar L.M. Hepatitis C: a metabolic liver disease. Gastroenterology 126 (2004) 917-919
3. Leandro G., Mangia A., Hui J., Fabris P., Rubbia-Brandt L., Colloredo G., et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 130 (2006) 1636-1642
4. Kumar D., Farrell G.C., Fung C., and George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology 36 (2002) 1266-1272
5. Castera L. Steatosis, insulin resistance and fibrosis progression in chronic hepatitis C. Minerva Gastroenterol Dietol 52 (2006) 125-134
6. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37 (2003) 917-923
7. Church T., Kuk J., Ross R., Priest E.L., Biltoft E., and Blair S.N. Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology 130 (2006) 2023-2030
8. Hamaguchi M., Kojima T., Takeda N., Nakagawa T., Taniguchi H., Fujii K., et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143 (2005) 722-728
9. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
10. Mohsen A., Easterbrook P., Taylor C., Portmann B., Kulasegaram R., Murad S., et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 52 (2003) 1035-1040
11. Agarwal K., Fiel M., Uriel A.J., Moorehead L., Kontorinis N., Thung S., et al. Correlation of insulin resistance with steatosis and fibrosis in hepatitis C and HIV co-infection: cross-sectional analysis of 101 patients. Hepatology 40 (2004) 587A
12. Neau D., Winnock M., Castera L., Bail B.L., Loko M.A., Geraut L., et al. Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hepatites virales CO3 Aquitaine Cohort. J Acquir Immune Defic Syndr 45 (2007) 168-173
13. Marks K.M., Petrovic L.M., Talal A.H., Murray M.P., Gulick R.M., and Glesby M.J. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect Dis 192 (2005) 1943-1949
14. Monto A., Dove L.M., Bostrom A., Kakar S., Tien P.C., and Wright T.L. Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection. Hepatology 42 (2005) 310-316
15. Gaslightwala I., and Bini E.J. Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol 44 (2006) 1026-1032
16. Jerico C., Knobel H., Montero M., Ordoñez-Llanos J., Guelar A., Gimeno J.L., et al. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care 28 (2005) 132-137
17. Fortgang I.S., Belitsos P.C., Chaisson R.E., and Moore R.D. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol 90 (1995) 1433-1436
18. Miller K.D., Cameron M., Wood L.V., Dalakas M.C., and Kovacs J.A. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 133 (2000) 192-196
19. Grunfeld C., Kotler D.P., Shigenaga J.K., Doerrler W., Tierney A., Wang J., et al. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 90 (1991) 154-162
20. Shor-Posner G., Basit A., Lu Y., Cabrejos C., Chang J., Fletcher M., et al. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med 94 (1993) 515-519
21. Bergersen B.M., Schumacher A., Sandvik L., Bruun J.N., and Birkeland K. Important differences in components of the metabolic syndrome between HIV-patients with and without highly active antiretroviral therapy and healthy controls. Scand J Infect Dis 38 (2006) 682-689
22. McGovern B., Ditelberg J., Taylor L., Gandhi R.T., Christopoulos K.A., Chapman S., et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 43 (2006) 365-372
23. Alberti A., Clumeck N., Collins S., Gerlich W., Lundgren J., Palù G., et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 42 (2005) 615-624
24. Tien P.C. Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office. Am J Gastroenterol 100 (2005) 2338-2354
25. Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., Lissen E., Gonzalez-García J., Lazzarin A., et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 351 (2004) 438-450
26. Lissen E., Clumeck N., Sola R., Mendes-Correa M., Montaner J., Nelson M., et al. Histological response to pegIFNα-2α (40KD) plus ribavirin in HIV-hepatitis C virus co-infection. AIDS 20 (2006) 2175-2181
27. Hung C., Kuo F., Wang J., Lu S.N., Hu T.H., Chen C.H., et al. Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy. Antivir Ther 11 (2006) 483-489
28. Patton H., Patel K., Behling C., Bylund D., Blatt L.M., Vallée M., et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 40 (2004) 484-490
29. Poynard T., Ratziu V., McHutchison J., Manns M., Goodman Z., Zeuzem S., et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38 (2003) 75-85
30. Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995) 696-699
31. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005) 1313-1321
32. Satterthwaite F.W. An approximate distribution of Estimates of Variance Components. Biometrics Bulletin 2 (1946) 110-114
33. Agresti A. Categorical data analysis. 2nd ed. (2002), Wiley
34. Bani-Sadr F., Carrat F., Bedossa P., Piroth L., Cacoub P., Perronne C., et al. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors. AIDS 20 (2006) 525-531
35. Bugianesi E., Marchesini G., Gentilcore E., Cua I.H., Vanni E., Rizzetto M., et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis. Hepatology 44 (2006) 1648-1655
36. Lapadula G., Torti C., Paraninfo G., Castelnuovo F., Uccelli M.C., Costarelli S., et al. Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy. Antivir Ther 11 (2006) 521-527
37. Mokrzycki M., Harris C., May H., Laut J., and Palmisano J. Lactic acidosis associated with stavudine administration: a report of five cases. Clin Infect Dis 30 (2000) 198-200
38. Jacobson D.L., Tang A.M., Spiegelman D., Thomas A.M., Skinner S.L., Gorbach S.L., et al. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr 43 (2006) 458-466
39. Gazzaruso C., Sacchi P., Garzaniti A., Fratino P., Bruno R., and Filice G. Prevalence of metabolic syndrome among HIV patients. Diabetes Care 25 (2002) 1253-1254
40. Tural C, Romero M, Solá R, Planas R, Viloria M, Gimenez M, et al. Insulin resistance in a prognostic factor of poor response to peg-interferon-alpha-2a + ribavirin in HCV + HIV patients. 13th Conferences on Retroviruses and Opportunistic Infections. Abstract 863.
41. Romero-Gomez M., Del Mar Viloria M., Andrade R.J., Salmerón J., Diago M., Fernández-Rodríguez C.M., et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128 (2005) 636-641
42. Lonardo A., Lombardini S., Scaglioni F., Carulli L., Ricchi M., Ganazzi D., et al. Hepatic steatosis and insulin resistance: does etiology make a difference?. J Hepatol 44 (2006) 190-196